Abstract:Glycogen storage disease type VI (GSD-VI; also known as Hers disease, liver phosphorylase deficiency) is caused by mutations in the gene coding for glycogen phosphorylase (PYGL) leading to a defect in the degradation of glycogen. Since there are only about 40 patients described in literature, our knowledge about the course of the disease is limited. In order to evaluate the long-term outcome of patients with GSD-VI, an observational retrospective case study of six patients was performed at the University Children's Hospital Zurich. The introduction of small, frequent meals as well as cornstarch has led to normal growth in all patients and to normalization of liver transaminases in most patients. After starting the dietary regimen, there were no signs of hypoglycemia. However, three of six patients showed persistent elevation of triglycerides. Further, we identified four novel pathogenic PYGL mutations and describe here their highly variable impact on phosphorylase function.Conclusions: After establishing the diagnosis, dietary treatment led to metabolic stability and to prevention of hypoglycemia. Molecular genetics added important information for the understanding of the clinical variability in this disease. While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.<table class="a-plus-plus table default-table float-no id-taba"><tbody class="a-plus-plus tbody"><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is Known:• Glycogen storage disease type VI (GSD-VI) is a metabolic disorder causing a defect in glycogen degradation. Dietary treatment normally leads to metabolic stability and prevention of hypoglycemia.• However, our knowledge about the natural course of patients with GSD-VI is limited.</td></tr><tr class="a-plus-plus row"><td class="a-plus-plus entry nameend-c2 namest-c1">What is New:• While outcome was overall excellent in all patients, half of the patients showed persistent hypertriglyceridemia even after initiating treatment.• Molecular genetics added important information for the understanding of the clinical variability in this disease.</td></tr></tbody></table>

Diagnosis and Follow‐up of Glycogen Storage Disease (GSD) Type VI from the Largest GSD Center in China

Novel PYGL mutations in Chinese children leading to glycogen storage disease type VI: two case reports

Genotypic and phenotypic features of 39 Chinese patients with glycogen storage diseases type I, VI, and IX

Glycogen Storage Disease Type VI Can Progress to Cirrhosis: Ten Chinese Patients with GSD VI and a Literature Review

Glycogen storage disease type VI can progress to cirrhosis: ten Chinese patients with GSD VI and a literature review.

A Novel, Recurrent, 3.6-Kb Deletion in the PYGL Gene Contributes to Glycogen Storage Disease Type VI

Genotypic and phenotypic characteristics of 12 chinese children with glycogen storage diseases

Clinical features and PHKG2 gene mutation analysis of 5 Chinese patients with glycogen storage disease Ⅸc

Report of 7 cases of glycogen storage disease type VI and type IXa

The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI

Three novel mutations of the G6PC gene identified in Chinese patients with glycogen storage disease type Ia

Clinical and genetic features of patients with glycogen storage disease type Ⅸa:An analysis of 20 cases

[Clinical Characteristics and Genetic Analysis of a Chinese Pedigree Affected by Glycogen Storage Disease Type Ia with Gout As the First Manifestation].

A patient with glycogen storage disease type Ia combined with chronic hepatitis B infection: a case report

Genetic Analysis and Clinical Assessment of Four Patients with Glycogen Storage Disease Type IIIa in China

Glycogen storage disease type VI: clinical course and molecular background

Expanding the clinicopathological-genetic spectrum of glycogen storage disease type IXd by a Chinese neuromuscular center

Genetic analysis and long-term treatment monitoring of 11 children with glycogen storage disease type IIIa

[Infant glycogen storage disease type Ⅳ: a clinicopathological and genetic characteristics analysis of five cases]

Molecular, Biochemical, and Clinical Characterization of Thirteen Patients with Glycogen Storage Disease 1a in Malaysia

Clinical and genomic study of the infant with glycogen storage disease typeⅡ